Floyd Petersen Sells 500 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd Petersen sold 500 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $27.20, for a total value of $13,600.00. Following the sale, the director owned 76,031 shares in the company, valued at $2,068,043.20. The trade was a 0.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Amphastar Pharmaceuticals Trading Up 0.9%

AMPH stock opened at $26.75 on Friday. The firm’s fifty day simple moving average is $27.30 and its two-hundred day simple moving average is $25.54. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of 10.02 and a beta of 0.75. The company has a quick ratio of 2.21, a current ratio of 3.29 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $53.96.

Institutional Trading of Amphastar Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in Amphastar Pharmaceuticals by 4,151.3% during the 1st quarter. GAMMA Investing LLC now owns 38,644 shares of the company’s stock valued at $1,120,000 after purchasing an additional 37,735 shares during the period. Cambridge Investment Research Advisors Inc. increased its holdings in Amphastar Pharmaceuticals by 14.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 13,790 shares of the company’s stock valued at $400,000 after buying an additional 1,694 shares during the period. Picton Mahoney Asset Management raised its stake in Amphastar Pharmaceuticals by 6,600.0% in the first quarter. Picton Mahoney Asset Management now owns 1,608 shares of the company’s stock worth $46,000 after buying an additional 1,584 shares in the last quarter. Graham Capital Management L.P. purchased a new stake in Amphastar Pharmaceuticals during the first quarter worth $766,000. Finally, Allspring Global Investments Holdings LLC boosted its position in Amphastar Pharmaceuticals by 9.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,326 shares of the company’s stock valued at $434,000 after acquiring an additional 1,262 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on AMPH shares. Piper Sandler dropped their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research report on Friday, August 8th. Needham & Company LLC raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research note on Tuesday, August 12th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research report on Saturday, September 27th. Finally, Bank of America increased their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of “Hold” and an average target price of $31.60.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.